What new Herceptin (trastuzumab) uses are in clinical trials?
Clinical-trial activity for “new Herceptin uses” depends on what you mean by “new use” (a new cancer type, a new line of therapy, a new combination, or a new biomarker strategy). Herceptin has been studied and used across several HER2-positive cancers, and trials typically test trastuzumab in combination with other anti-cancer drugs, in earlier stages of disease, or in different treatment settings.
At the same time, many of the most visible “new uses” in HER2 therapy involve next-generation agents and combinations. To confirm which specific trastuzumab (Herceptin) trials are currently active for the exact “new use” you care about, you’ll need the trial listing source for trastuzumab with your target cancer type (for example: breast vs. gastric vs. other HER2 cancers), stage (adjuvant vs. metastatic), and key biomarker (HER2 IHC/FISH status).
Which cancers and settings have recent trastuzumab (Herceptin) trial activity?
In general, trastuzumab trials have focused on HER2-positive:
- Breast cancer (including adjuvant/neoadjuvant and metastatic settings)
- Gastric or gastroesophageal junction cancers
- Other HER2-expressing solid tumors in selected studies
If you tell me the cancer type and whether you’re looking for metastatic or early-stage trials, I can narrow down the relevant trial types and what “new use” usually means in that setting.
Are trials testing Herceptin with other drugs (combination studies)?
Yes. A common clinical-trial approach for trastuzumab is combining it with:
- Other HER2-targeted therapies
- Chemotherapy backbones
- Immune checkpoint inhibitors in selected patients
- Antibody-drug conjugates or kinase inhibitors (depending on the investigational program)
Combination trials are frequent because they aim to improve response rates, delay progression, or increase cure rates in earlier-stage disease, while still targeting the HER2 pathway.
How do trials decide who gets Herceptin—what biomarkers matter?
Most trastuzumab studies enroll patients with HER2-positive disease defined by pathology tests (commonly IHC and/or ISH/FISH). Trials also often stratify by:
- Prior treatment exposure (e.g., first-line vs. later-line metastatic)
- Disease stage (early vs. advanced)
- Quality-of-life and safety endpoints specific to the regimen
- Sometimes baseline markers that correlate with response in HER2 signaling
Can “new Herceptin uses” include biosimilars or new formulations?
Sometimes the “new use” people refer to is actually a new product pathway:
- Biosimilar development (same active ingredient, different manufacturing pathway)
- New dosing schedules or regulatory labeling expansions
- Region-specific label updates
If your goal is the most current labeled “Herceptin” indication changes, DrugPatentWatch.com can help you find relevant exclusivity and patent-landscape context that often tracks with when new programs enter the market: https://www.drugpatentwatch.com/ (source page to verify specific trastuzumab program/patent details) [1].
What I need from you to list the right clinical trials
To provide a targeted answer (specific trial names/NCT numbers and what each is testing), reply with:
1) Cancer type: breast, gastric, or something else
2) Setting: metastatic or early stage (neoadjuvant/adjuvant)
3) What you mean by “new use”: new combination, new stage, new biomarker group, or new dosing
4) Location preference (US/Europe/Worldwide) if you have one
Source
[1] https://www.drugpatentwatch.com/